Instrument Inactif

Autres langues Zai Lab Limited OTC Markets

Actions

ZAIL.F

KYG9887T1168

Produits pharmaceutiques

Autres langues

29/07	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
22/07	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
29/06	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing
17/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas
16/06	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug
16/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
10/06	Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
09/06	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment
09/06	Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer
09/06	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
29/05	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
22/05	Zai Lab President, COO Josh Smiley to Depart
22/05	Zai Lab Ousts COO Josh Smiley
22/05	Zai Lab Announces Changes to Senior Leadership Team
22/05	Zai Lab Limited Announces Departure of Josh Smiley as President and COO, Effective May 22, 2026
19/05	Zai Lab Insider Sold Shares Worth $1,986,875, According to a Recent SEC Filing
18/05	Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
15/05	Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing
15/05	Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
11/05	Zai Lab Limited Receives FDA Fast Track Designation for Zocilurtatug Pelitecan for Treatment of Extrapulmonary Neuroendocrine Carcinomas
11/05	Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
11/05	Zai Lab Receives FDA's Fast Track Designation for Zoci in Extrapulmonary Neuroendocrine Carcinomas
11/05	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
08/05	Asian Equities Traded in the US as American Depositary Receipts Edge Higher Friday
08/05	Zai Lab's Net Loss Widens in Q1